Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China.

ABSTRACT:

Objective

To determine the cost effectiveness of molecular monitoring in patients with chronic myeloid leukemia in the chronic phase (CML-CP) compared to no molecular monitoring from a Chinese payer perspective.

Methods

Analyses were conducted using a semi-Markov model with a 50-year time horizon. Population data from multicenter registry-based studies of Chinese patients with CML-CP informed the model. Transition probabilities were based on time-to-event data from the literature. Utility values were obtained from published studies and were assumed to be the same for patients with and without molecular monitoring. Costs were based on values commonly used in the Chinese healthcare system, including drug acquisition, drug administration, follow-up, treatment for disease progre

SUBMITTER: Maheshwari VK 

PROVIDER: S-EPMC8544861 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature